From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2018 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从需要说服的候选者转变为已批准、指定、列入、合格、注册、报销或预先授权的选择,进入买家自身的采购、报销、处方集、规格、采购、网络、目录或计划系统,从而使得公司未来业务的相当一部分可以在没有每次单独销售事件的情况下实现,并且管理层是否传达了这种准入状态是新的,以至于它所释放的大部分量仍在前方。 在记录中,管理层讨论了VIVITROL和ARISTADA的销售,以及政策变化,如《支持患者和社区法案》的签署,该法案可能影响VIVITROL的获取。然而,管理层没有明确描述公司被添加到处方集、报销目录或任何具体买家系统,从而使其成为默认选择。他们提到ARISTADA INITIO被添加到超过30家医院的处方集中,以及SilverScript Medicare Part D处方集将在第四季度加入,但这是否构成“最近跨越”到默认状态?管理层表示,这些添加是最近的,并且他们预计覆盖范围将继续扩大。然而,他们并没有明确说这些添加意味着未来业务将无需每次销售事件即可自动流入。他们仍然在积极推广和销售产品。 此外,管理层讨论的联邦立法是潜在的,尚未完全实施,因此不是已获得的准入状态。他们提到“支持患者和社区法案”即将签署,但这是未来的事件,不是已经发生的。 因此,管理层没有描述公司已进入一个具体的买方系统,使得购买成为默认。他们描述的是持续的销售努力和政策倡导,而不是已建立的准入。因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.